Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 1.Conditions for Administering Bispecific Therapy

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

Now Viewing

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

Discussed in this segment are the challenges and best practices in managing transitions of patients receiving bispecific antibodies between different healthcare institutions. The focus is on ensuring seamless care transitions, particularly during the handoff phases between community centers and academic centers. Dr. Hanna emphasizes the importance of a strong working partnership between academic and community settings. In the community setting, where only a few hematologists may be REMS-certified for bispecific antibodies, collaboration with academic cohorts becomes crucial.

Panelists further highlight the need for effective communication and information exchange between providers during transitions. They discuss the development of relationships and partnerships over the years to ensure a smooth migration for patients. The use of software facilitates communication between EMRs, even in non-EPIC-run institutions, improving the sharing of patient information.

The discussion also touches on the involvement of clinical pharmacists and the importance of peer-to-peer discussions between providers to understand the patient's history, including adverse events like CRS and ICANS. The conversation emphasizes the need for comprehensive medical records, assessment of the patient's health status, and protocols for managing potential adverse events.

Dr. Chang adds insights into the plans and protocols required when receiving a patient back from a different institution. This includes obtaining comprehensive medical records, establishing communication with previous providers, conducting thorough assessments, and implementing protocols for managing adverse events. She stresses the importance of administrative considerations, including billing, insurance coverage, and authorization, to facilitate a smooth transition of care.

Overall, the discussion underscores the collaborative efforts and strategic planning needed to ensure patient safety, efficiency, and a seamless continuum of care during transitions between healthcare institutions.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.